Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Patient advocates are pushing FDA to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.